Hemogenyx Pharmaceuticals Plc (LON: HEMO) has entered into CAR-T agreement with University of Pennsylvania.
- The company has entered into a Sponsored Research Agreement with an aim to advance the CAR (Chimeric Antigen Receptor) T-cells, known as “HEMO-CAR-T" developed by the company toward clinical trials.
- The agreement is considered as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukaemia.
- On 11 August 2020, at the time of writing, GMT 08:05 AM, HEMO shares were trading at GBX 10.13, up by 1.17 points or 13% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.